Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Laboratory Medicine, Fooyin University Hospital, Pingtung, Taiwan; Department of Medical Laboratory Science and Biotechnology, Fooyin University, Kaohsiung, Taiwan.
Institute of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan.
Am J Infect Control. 2011 Jun;39(5):408-414. doi: 10.1016/j.ajic.2010.07.010. Epub 2011 Jan 21.
The national hepatitis B virus (HBV) vaccination program was launched in Taiwan in 1984. After November 1992, a recombinant HBV vaccine replaced the plasma-derived HBV vaccine.
A total of 1,812 nursing and medical technology freshman students was tested to evaluate their waning immunity toward hepatitis B. In the 2007 (2008) academic year, 438 (382) students testing nonprotective antibodies received 3 (1) booster doses of HBV vaccine according to suggestions from Taiwan's Center for Disease Control (CDC).
The seroprevalences of hepatitis B surface antigen (+) were 0.8% and 0.7% in the plasma-derived and recombinant group, respectively; for antibody to hepatitis B surface antigen (anti-HBs) (+), they were 43.2% and 33.3% (P < .001), respectively. In the 2007 freshman group, 99.1% of the students previously vaccinated with plasma-derived HBV vaccine exhibited anti-HBs seroconversion. In the 2008 freshman group, the booster dose induced anti-HBs seroconversions of 92.1% and 95.9% in the students who had received the plasma-derived and recombinant HBV vaccine, respectively (P = .370).
Most students exhibited signs of immune memory after receiving the booster, regardless of having received plasma-derived or recombinant HBV. Only a small number of vaccinees lost their immune memory after 16 years, suggesting that some students might benefit from boosting before proceeding to clinical practice.
台湾于 1984 年启动了全国乙型肝炎病毒（HBV）疫苗接种计划。1992 年 11 月之后，重组 HBV 疫苗取代了血浆衍生的 HBV 疫苗。
共有 1812 名护理和医学技术专业的新生接受了乙型肝炎病毒衰减免疫检测。在 2007（2008）学年，根据台湾疾病控制中心（CDC）的建议，438（382）名未检测到保护性抗体的学生接受了 3（1）剂 HBV 疫苗加强针。
血浆衍生组和重组组的乙型肝炎表面抗原（HBsAg）阳性率分别为 0.8%和 0.7%；抗乙型肝炎表面抗原（抗-HBs）阳性率分别为 43.2%和 33.3%（P<0.001）。在 2007 年新生组中，99.1%之前接种过血浆衍生 HBV 疫苗的学生出现抗-HBs 血清转化。在 2008 年新生组中，接受血浆衍生和重组 HBV 疫苗的学生加强针分别诱导了 92.1%和 95.9%的抗-HBs 血清转化（P=0.370）。
大多数学生在接受加强针后出现免疫记忆迹象，无论接种的是血浆衍生还是重组 HBV。只有少数疫苗接种者在 16 年后失去了免疫记忆，这表明一些学生在进入临床实践之前可能需要加强免疫。
